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Abstract
Monoclonal antibodies (MAbas) constitute remarkable tools to analyze the relationship between the structure and the
function of a protein. By immunizing a mouse with a 29mer peptide (K159) formed by residues 147 to 175 of the HIV-1
integrase (IN), we obtained a monoclonal antibody (MAba4) recognizing an epitope lying in the N-terminal portion of K159
(residues 147–166 of IN). The boundaries of the epitope were determined in ELISA assays using peptide truncation and
amino acid substitutions. The epitope in K159 or as a free peptide (pep-a4) was mostly a random coil in solution, while in
the CCD (catalytic core domain) crystal, the homologous segment displayed an amphipathic helix structure (a4-helix) at the
protein surface. Despite this conformational difference, a strong antigenic crossreactivity was observed between pep-a4 and
the protein segment, as well as K156, a stabilized analogue of pep-a4 constrained into helix by seven helicogenic mutations,
most of them involving hydrophobic residues. We concluded that the epitope is freely accessible to the antibody inside the
protein and that its recognition by the antibody is not influenced by the conformation of its backbone and the chemistry of
amino acids submitted to helicogenic mutations. In contrast, the AA RGlu mutations of the hydrophilic residues Gln148,
Lys156 and Lys159, known for their interactions with LTRs (long terminal repeats) and inhibitors (5 CITEP, for instance),
significantly impaired the binding of K156 to the antibody. Moreover, we found that in competition ELISAs, the processed
and unprocessed LTR oligonucleotides interfered with the binding of MAba4 to IN and K156, confirming that the IN a4-helix
uses common residues to interact with the DNA target and the MAba4 antibody. This also explains why, in our standard in
vitro concerted integration assays, MAba4 strongly impaired the IN enzymatic activity.
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Introduction
HIV-1 replication requires the use of three enzymes encoded by
the Gag/Pol gene: reverse transcriptase, protease and integrase
(IN) [1,2]. After virus entry into host immune cells, reverse
transcriptase converts the HIV-1 RNA into DNA. Then IN carries
out integration of viral DNA into the host chromosome through a
two-step process: 39 processing and strand transfer. Initially, a
dinucleotide GT is excised from the 39 ends (transferred strand) of
nascent DNA in the cytoplasm. A multi-component pre-integra-
tion complex, including the processed viral DNA and IN, is
chaperoned into the nucleus. Here occurs the covalent insertion of
HIV-1 DNA into the host chromosome [3,4,5].
The HIV-1 IN as the other retroviral INs comprises three
distinct domains [6,7]: the Nterminal domain (NTD), the C-
terminal domain (CTD) and the core catalytic domain (CCD).
NTD (residues 1-50) exhibits a three helix bundle organization
with a helix-turn-helix motif bound to Zn2+ [8]. CTD (residues
213–288) contains a structure similar the SH3 motif involved in
protein-protein interactions and is rich in Lys and Arg residues
distributed on b-strands [9,10]. The central CCD (residues 51–
212) is formed of 5 b-strands and 6 a helices and harbors the
conserved catalytic triad of acidic residues D, D, E -that binds
either one or two divalent ions (i.e. Mg2+ or Mn2+) - embedded in
an RNase fold [11,12,13,14,15,16,17,18,19].
The three domains taken separately or coupled in two-domain
fragments (CCD-CTD and NTD-CCD) form a dimer [20],
although the tetramer emerges as the functional association
[21,22,23,24,25]. Both the 39-processing and the DNA joining
reactions have been reproduced in in vitro assays with the
recombinant IN and duplex oligonucleotides mimicking the U3/
U5 LTR extremity with a processing site CAQGT at the 39-end of
the transferred strand. Such 17 to 21 base-pair oligonucleotides
behave in vitro as both DNA donor and DNA acceptor. A large
number of mutations or modifications have suggested the key role
of the six outermost base-pairs for binding of IN to virus DNA
[1,12]. This has been recently confirmed by the crystal structure of
the Protoype Foamy Virus (PFV) in complex with a 39-processed
cognate LTR DNA [25]. Analysis of the crystal structure of the
above complex has further highlighted the key role held by the
amphipatic a4-helix of CCD in the recognition of virus.
DNA, this lending credence to our previous results [26,27,28,29].
Actually, the strongest binding determinants of the a4-helix are: its
global accessibility at the CCD surface, and, especially, the large
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e16001exposition to solvent of the polar/charged side chains of residues as
for instance Gln148, Lys156 and Lys159 (Fig. 1-A). Implication of
these residues in binding of IN to virus DNA and strand transfer
inhibitors [1] has been shown by mutagenesis [12,30,31,32],
chemical modifications [30,33,34,35,36,37,38] and spectroscopy
methodsinsolution[26],aswellasanalysisofthecrystalstructure of
the 5CITEP-CCD complex [39] and drug resistance mutations
[40,41,42,43,44].
To go thoroughly into above points and related questions, we
prepared monoclonal antibodies against a synthetic peptide
named K159 reproducing the sequence 147–175 of the HIV-1
IN [45]. Within the CCD crystal structure the corresponding
segment carries the a4- helix in its N-terminal portion (residues
from about 150 to 166), a loop in its center (residues 166–171) and
the beginning of the a5-helix in its C-terminal portion (residues
172–175) [15,16,19]. Indeed, the whole K159 peptide appears
highly antigenic. About 10 year ago we had already characterized
a functional epitope in its C-terminal portion [46]. Once purified
to the stage of monospecific the corresponding polyclonal
antibodies were able to recognize with high affinity the isolated
C-terminal portion, the entire K159, CCD and the full-length
enzyme. They were also strong antagonists of the IN enzymatic
activity [46]. Here, an optimal epitope was found in the N-
terminal portion (residues 147–166), using peptide truncation and
ELISA assays. The monoclonal antibody prepared against K159,
MAba4, recognizes with almost similar affinity the epitope in a
random coil structure (peptide-a4 either isolated or include in
K159) or in a helical conformation (within either IN or the peptide
K156, an analogue of the peptide-a4 stabilized into a helical
conformation thanks to seven helicogenic substitutions performed
in selected positions) (Fig. 1B) [26]. These substitutions while
efficient to stabilize the conformation do not partipate to the
complex formation. In contrast, those substitutions performed on
residues Gln148, Lys156 and Lys159 [26,47] which contribute to
the binding of IN to the virus DNA and also the 5CITEP inhibitor
[39], have deleterious effects on the binding to MAba4. The
antibody incubated with IN inhibits its enzymatic activity in in vitro
concerted integration assays [22,48,49]. Use of LTR DNAs in
competition ELISA assays reveals that these latter compete with
the antibody for the binding to IN and K156. We also noted that
the unprocessed version of LTR DNA is a better competitor than
the processed version for the binding of MAba4 to IN. These
Figure 1. Structural properties of the HIV-1 IN a4-helix. A: In the various crystal structures of the IN CCD, the a4-helix is located at the protein
surface with its hydrophobic residues turned towards the interior of the protein and the polar residues Gln148, Lys156 and Lys159 directed outwards
from the protein, prone to interact with the antibody and the DNA. B: The a-4 helix and its structural analogue K156 are represented as a helical
wheel, with the N-terminal residue S147 positionned at the top on the circle. Most of substitutions converting pep-a4 into the analogue K156 are
hydrophobics and rather isosterics (GlyRAla, ValRLeu, IleRLeu…). The global effect of mutations is an improvement of the helicity [26]. Note that
residues Gln148, Lys156, Lys159 are aligned on a narrow ridge on the hydrophilic/charged surface of the helix.
doi:10.1371/journal.pone.0016001.g001
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that IN had a higher affinity for unprocessed DNA than for
processed DNA, thus highlighting the role of the GT39
dinucleotide in the stabilization of the IN-DNA complex.
Materials and Methods
All animal work has been conducted according to relevant
national and international guidelines. All animal care and
procedures were in accordance with institutional guidelines and
European regulations. Animal work has been done in INSERM
agreated laboratory and production of antibodies was for the only
aim of fundamental research. Therefore, no ethic committee
approval was needed.
Agre ´ment Nu: C94-076-32 du 26 november 2009
CNRS-SEAT-UPS44
7 rue Gue Mo ˆquet- Ba ˆtiment G
94800 VILLEJUIF
Peptides and samples
The peptides used in the present work either reproduce or
derive from a segment contained in the CCD of IN (Fig. 2A). Most
of them have been already used in previous studies dealing with
the identification of polyclonal antibodies against IN [46] and the
binding of IN to LTR DNAs [26]. These were prepared according
to the Fmoc [N-(9-fluorenyl) methoxycarbonyl] procedure and
purified with reverse-phase high pressure liquid chromatography.
The molecular mass and purity of each peptide was confirmed by
electrospray ionization mass spectrometry. The peptide concen-
tration was generally determined from the UV signal of Tyr or
Figure 2. Peptides and oligonucleotides used to prepare and study the epitope. A: The 29-mer peptide K159 (residues 147–175 in IN of
HXB2) was used as immunizing peptide [45,46]. To delimit the epitope and analyze the properties we used several other peptides: pep-a4
reproducing the a4-helix sequence; IN636, a C-terminal fragment of K159 that has shown epitope properties in a previous work [46]; IN638, a N-
terminal fragment of K159; INH5, a strong inhibitor of IN [46], that includes a loop region (residues 167–171) and the beginning of the a5-helix
(residues 172–187); K156, a structural analogue of pep-a4, that is constrained into helix through seven helicogenic substitutions [26]; HTH (a4-helix-
loop-a5-helix) [27]; E156, E159 and E148 (structural analogues of K156 in which residues Lys156, Lys159 and Gln148 has been respectively replaced by
Glu); K156-E, the elongated K156 peptide ([136–146]-K156); and the peptide control that derives from K156 from six AARGlu mutations. B: Once
folded into hairpin structure around the central trinucleotide TTT, the three LTRoligonucleotides mimic the U5 LTR extremity. LTR17 carries a 7 pb
stem corresponding to the most important region for IN binding. LTR34 carries a 17 pb stem, a minimum DNA size for successful reaction of
integration in vitro. It represents an unprocessed version of U5 LTR, while LTR32 corresponds to the processed version with its 15 bp and its 59CA
hanging dipeptide. The DNA duplex CRE (cAMP responsive element) is used as a control.
doi:10.1371/journal.pone.0016001.g002
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absorption coefficient of 1197 M-1cm-1 at 280 nm (Tyr) and 5600
M-1cm-1 (Trp).
DNA samples
The oligonucleotides were purchased from Eurogentec (Fig. 2B).
The three LTRs of oligonucleotides were designed to adopt a
hairpin structure. Compared with linear duplexes, they present a
higher stability at the low concentrations used in ELISA
experiments. LTR34 and LTR17 contain a 17-bp stem and a 7-
bp stem, respectively, corresponding to the outermost domains of
unprocessed U5 LTR, while LTR32 represents the 39processed
version of U5 LTR. The loop is formed around the three thymine
sequence (TTT) inserted at the oligonucleotide centre. The
oligonucleotide duplex CRE (cAMP responsive element) was used
as a control.
HIV-1 IN
Standard purification was performed essentially as previously
described [50]. The soluble fraction containing the HIV-1 IN
obtained from JSC 310 (IN) expressing IN protein was loaded on a
Hitrap butyl-sepharose 4B column (1 ml, Pharmacia-LKB),
washed with LSC buffer (50 mM HEPES pH 7.6, 0.2 M NaCl,
0.1 mM EDTA, 1 mM DTT, 7 mM CHAPS, 10% glycerol) and
equilibrated with 5 volumes HSC buffer (50 mM HEPES pH 7.6,
0.2 M NaCl, 1 M ammonium sulfate, 0.1 mM EDTA, 1 mM
DTT, 7 mM CHAPS). Proteins were eluted by a decreasing
ammonium sulfate gradient (1 to 0 M). Fractions containing IN
activity were pooled and 7 mM CHAPS was added. Pooled
fractions were 1/3 diluted with 50 mM HEPES pH 7.6, 0.1 mM
EDTA, 1 mM DTT, 10% glycerol, 7 mM CHAPS and loaded on
a Hitrap Heparine Sepharose CL-4B column (1 ml, Pharmacia-
LKB), washed with 5 volumes HS buffer (50 mM HEPES pH 7.6,
1 M NaCl, 0.1 mM EDTA, 1 mM DTT, 10% glycerol, 7 mM
CHAPS) and equilibrated with a linear NaCl gradient (0 to 1 M
NaCl). Fractions containing IN activity (eluted at 300 mM NaCl
concentration) were pooled and concentrated or not by ultrafil-
tration (Centricon Millipore), followed by addition of 7 mM
CHAPS. ZnSO4, 50 mM was added in the stock fraction. Purified
IN (10 to 50 mM) was kept at 280uC (the NaCl concentration of
the stock was 300 mM). Proteins were analyzed by electrophoresis
in a 12% SDS-PAGE and western blotting using a polyclonal anti-
IN antibody (Invitrogen).
Antibody production and purification
Seven different monoclonal antibodies were selected according
to a standard procedure. Among these two antibodies bound the
peptide K159 at its N-terminal and C-terminal extremities with
high affinity. We selected MAba4 recognizing the N-terminal
extremity for the present study. Hybridoma cells were produced
by fusing myeloma cells with the spleen cells from a C57 Black
mouse that was immunized with the peptide K159, homologous to
residues 147–175 of IN from HXB2D viral strain (Fig. 2A). This
sequence is highly conserved within all HIV-1 strains and presents
a very good homology with other retroviral integrases and
tranposases [11,51]. We had previously used this peptide to raise
polyclonal antibodies in the rabbit [46]. Here, the peptide was
coupled to Keyhole Limpet Hemocyanin (KLH-Pierce) with
benzidine and injected to mice (200 mg per injection). The first
injection was given subcutaneously in complete Freund’s adjuvant.
A booster injection was given on day 20 that is nearly three weeks
after the first injection. The mice were bled on day 40. Cells
isolated from the spleen were fused with myeloma cells (X63-Ag8)
using PEG (polyethylene glycol).
Fused cells were then selected in a HAT (hypoxanthine
aminopterin thymidine) medium. Hybridomas were harvested,
diluted, and clones were grown from single parent cells on
microtiter wells. MAba4 was purified from the corresponding
hybridoma cell culture supernatant. An enzyme-linked immuno-
sorbent assay (ELISA) was performed against K159 and HIV-1 IN
and permitted to calculate the antisera titers. The inability of the
antibody to bind to protein G in affinity column shows that this
antibody belongs to IgA type. Purification of MAba4 was
performed on a sepharose 4B column coupled with anti-IgA and
controlled by a migration on a SDS-PAGE. Antibody concentra-
tion was determined by spectrophotometry at 280 nm.
Immunoassays
We used simple ELISA assays to locate the antibody-binding
region within the K159 peptide. The use of truncated K159
peptides and other related peptides (Fig. 2A) provided the amino
acid positions of the epitope boundaries. Competition ELISAs
were also used in order to assess the ability of IN target DNAs to
move the antibody from its complex with IN or K156 (Fig. 2B).
5 mg of antigen (synthetic peptide or IN) were incubated in the
wells of the reaction’s plate. The plate was then incubated at 4uC
overnight, and saturated with a 0.5% solution of bovine gelatin for
30 minutes at 37uC. 50 ml of MAb at 20 mg/ml were then added
to each well and the mixture was incubated for 1 hour at 37uC.
Wells were washed 5 times with the washing solution (PBS 1X
+0.1% Tween 20) and 150 mL secondary Abs labeled with
peroxidase and were distributed to sink to the dilution of 1/1000
in dilute solution (PBS 1X +0.1% Tween 20+0.5% gelatin). The
plate was incubated 1 hour at 37uC to allow the binding of the
secondary antibody. Revelation was performed by enzymatic
reaction after washing sink with wash solution. 50 mL solution
revelation (5 mg Ortho-Phenylenediamine: OPD) dissolved in
10 mL development (0.1 M citric acid +0.1 M trisodium citrate,
pH=6), and 10 mL H2O2 at 30% were added to each well and
the plate was placed 20 to 30 minutes in the dark. The reaction
was stopped with 25 mL hydrochloric acid 10
3 M and reading was
performed at 450 nm. U5/U3 LTR DNAs are targets of IN and
K156, the stabilized analogue of pep-a4 mimicking the a4-helix of
IN. To understand whether these oligonucleotides compete with
MAba4 for the binding to IN or K156, competition ELISAs were
performed with LTR17, LTR32, and LTR34, taking CRE (cAMP
responsive element) and a mouse IgA antibody (Sigma, clone
TEPC15) as controls. 5 mg of antigen (IN or K156) and 50 ng of
DNA were preincubated at 37uC for 1 hour, and wells were
coated with the IN-DNA complex and incubated overnight at
4uC.
IN activity assays
Standard concerted integration reactions were performed as
described previously [52], except that no cellular proteins were
added. Briefly, purified HIV-1 IN (1 pmole, 50 nM) was
preincubated with both the 59-end-labeled donor DNA (10 ng)
containing the 39-processed U3 and U5 LTR sequences and the
target DNA plasmid pBSK+ (100 ng) at 0uC for 20 min in a total
volume of 5 ml. Then the reaction mixture (20 mM HEPES,
pH 7.5; 10 mM DTT; 7.5 mM MgCl2; 10% DMSO; 8% PEG)
was added and the reaction proceeded for 90 min. In all the
reactions the final NaCl concentration was adjusted at 30 mM.
Incubation was stopped by adding a phenol/isoamyl alcohol/
chloroform mix (24/1/25 v/v/v). The aqueous phase was loaded
on a vertical 1% agarose gel in the presence of 1% bromophenol
blue and 1 mM EDTA. After separation of the products, the gel
was treated with 5% TCA for 20 min, dried and autoradio-
Antigenic Peptide Element from HIV-1 Integrase
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after gel electrophoresis and autoradiography using the Image J
software. Both target and donor plasmids were kind gifts from Dr.
Karen Moreau (Universite ´ Claude Bernard-Lyon I, France).
The target corresponds to the plasmid pBSK+ (Stratagene, La
Jolla, California) carrying the zeocin resistance encoding gene.
The 294 bp pre-processed donor substrate was obtained as
described previously [22] and contains after cleavage by NdeI
the supF tRNA gene flanked by two pre-cleaved extremities
mimicking the 39-processed U3 and U5 LTR sequences. The
unprocessed donor was generated by cloning a donor containing
ScaI ends into a PGem-T vector (Promega) as previously described
[53]. The PGem-T-SupFScaI resulting vector was cleaved by ScaI
and the substrate fragment was purified.
Results
Epitope Mapping
An antigenicity profile prediction showed that the 147–175
sequence was more antigenic compared with the other IN
sequences [54]. Moreover, the N-terminal portion has been
shown high antigenic in the Los Alamos database (http://www.
hiv.lanl.gov/content/immunology).
The binding of MAba4 to IN, the antigenic peptide K159, and
other peptide fragments (Fig. 2A) was studied by ELISA (Fig. 3). In
these experiments, the signal intensity correlates to the ability of
MAba4 to bind peptides and the IN protein. Signal for maximum
interaction was observed with IN and K159, HTH, K156 and
pep-a4. The observation of a same binding intensity for IN, pep-
a4, K159 and HTH already suggests that the epitope coincides
with pepa4 and is freely accessible to the antibody in the enzyme.
The important loss of binding with the shorter IN636 peptide
confirms that the epitope covers the all pep-a4 length. The binding
conservation with INH5 further shows that the loop in between
the a4- and the a5- helices is not necessary to recognition.
However, comparison of pep-a4 with IN638 suggests that residues
Val and Arg at the C-terminal end of the a4-helix, just before the
loop, could participate to the interaction. Due to the high
conservation of the 147–175 sequence within the intergrases of all
HIV-1 strains, we can expect a good affinity binding of MAba4
also with these enzymes [11].
Impact of sequence and conformation on recognition
We know from our previous CD experiments that the antigenic
peptide K159 displays a high ratio of disordered secondary
structure in aqueous solution; which is also the case of pep-a4
taken in isolation [26,45,55]. We have seen above that pep-a4 and
K159 were recognized with a same high intensity by MAba4
(Fig. 3). Actually, it is also the case of the structural analogue of
pep-4, K156, bearing seven amino acid substitutions (Fig. 1A).
Most of these substitutions are helicogenic and concern hydro-
phobic residues which are buried in the CCD protein (Fig. 1B)
[27]. These mutations restore the helix secondary structure, so that
the resulting analogue K156 now mimics the a4-helix conforma-
tion displayed by the protein in the CCD crystal structure.
Overall, the inability of MAba4 to discriminate between a stable
and an unstable a4-helix reveals that the antibody binding is not
sensitive to the epitope conformation. Moreover, the antibody is
not measurably sensitive to the size and chemical nature of amino
acid side chains, mostly located in the hydrophobic surface of the
helix. In contrast, mutations performed in the hydrophilic surface
of the helix show that the recognition is sensitive to the change of
polar side chains exposed in this surface (Fig. 1A). The XRGlu
replacements in positions 156 (Lys), 159 (Lys) and 148 (Gln) of
K156 significantly impair the antibody recognition, each mutation
dereasing three times the binding intensity. In fact these residues
exert a key role in DNA cleavage and binding by IN [1,26]; they
also participate to the capture of the 5CITEP inhibitor by the IN
[39]. Moreover, the position 148 (Glu) of IN is a hotspot for
mutations conferring drug resistance, especially those induced by
raltegravir [56].
Figure 3. Identification of the epitope and residues that bind MAba4. The histogram represents the ELISA results provided by the binding of
the MAba4 to the immunizing peptide K159, shorter and longer peptides, analogues and IN. ELISA absorbances with its target molecule are
represented as a percentage of the mean absorbance for 12 experiments. The binding of MAba4 to peptide targets is expressed as the report of its
absorbance to the control peptide. Panel values are the mean 6 standard deviation (error bars) of three independent experiments.
doi:10.1371/journal.pone.0016001.g003
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light on the question of the epitope/a4-helix accessibility to
antibody and the possible masking effect of the well known flexible
loop (residues 140–147) before the a4-helix. The weaker binding
signal of K156-E compared with K156 suggests that the peptide
moiety (residues 136–146) containing the loop hinders the
recognition of the epitope by the antibody. Note that in the
different crystal CCD structures so far reported, the loop extends
beyond the area of the a4-helix. However, in the complex of the
PFV (prototype foamy virus) IN- very similar to the HIV-1 IN-
with its target DNA, the loop slightly folds back on the a4-helix
and participate to strong contacts with the DNA. This binding of
the loop (actually to the processed DNA) could somewhat prevent
a near adjustment of the a4-helix to the DNA [25] concerning the
binding of K156-E to the antibody, it could be also that the
flexible loop folds back on the helix and, thus, interferes with the
antibody recognition. The main victim of this particular folding
could be residue Gln148 located at the loop-helix junction.
In the HTH motif the hydrophobic residues belonging to the
amphipathic a4-helix participate to stabilizing interactions with
the a5-helix, while the three polar/charged residues Gln148,
Lys156 and Lys159 are exposed to solvent, free to contact any
binding partner [27,57]. Therefore, conservation of a high
intensity binding with HTH, similar to pep-a4, is not so surprising.
MAba4 hinders the binding of IN to DNA
The DNA fragments, LTR 17, 32 and 34 have been designed to
adopt monomolecular hairpin structures by folding around a 3-
thymine loop (TTT) located at the centre of the oligonucleotides
(Fig. 2B). The stems reproduce several versions of the U5 LTR
extremity of viral DNA The stem of LTR34 mimics the
unprocessed 17 bp version of the LTR extremity, and is sufficient
to carry out in vitro integration assays. The stem of LTR32
reproduces the processed version of LTR34, that is a stem with the
upper transferred strand lacking 39 GT (15 nucleotides) and the
lower non transferred strand (17 nucleotides including the
dangling 59AC). The shorter LTR version, LTR17 (7 bp), carries
the minimum DNA site required for IN binding [1]. The ability of
DNA to bind the epitope and impede the formation of the epitope-
antibody complex was measured in competition ELISAs (Fig. 4A).
The antibody was added to wells coated with IN and K156 either
free or incubated with DNA. The strongest inhibition was
Figure 4. Inhibition of binding of MAba4 to IN and K156 by DNA fragments. A: Histogram representation of competition ELISA results for
the competitive binding between DNAs and MAba4 to IN and K156. Wells were coated either with IN and K156 or with the complexes IN-DNA and
K156-DNA. IN or K156 where incubated either with DNA or added to the antibody- complex. From left to right: IN, IN-DNA complexes, K156, K156-
DNA complexes. Panel values are the mean 6 standard deviation (error bars) of three independent experiments. CRE (cAMP Responsive Element) was
used as control. B: Histogram representation of simple ELISA results for the binding of DNAs to MAba4. Panel values are the mean 6 standard
deviation (error bars) of three independent experiments. C: Histogram representation of an ELISA control for the competitive binding of DNAs to IN
and K156 realized in presence of a mouse IgA antibody.
doi:10.1371/journal.pone.0016001.g004
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Control tests showed that LTR oligonucleotides were unable to
interact with MAba4 (Fig. 4B) and that the CRE oligonucleotide
(Fig. 2B) was unable to interfere in the binding of MAba4 to IN
and K156.
All together, above results accredits the idea that the epitope/
a4-helix belongs to the DNAbinding domain of the enzyme
(Fig. 1A). Implication of the a4-helix into the binding of the
enzyme to the LTR extremities has been previously shown by
fluorescence anisotropy, circular dichroism, and NMR studies of
DNA-peptide complexes [26] and has been confirmed recently by
analysis of the crystal structure of PFV IN bound to its cognate
DNA [25]. The fact that LTR34 behaves as a better competitor
than LTR32 for the formation of the MAba4-K156 complex is
conform to our results on the binding of K156 to viral DNA.
MAba4 inhibits the in vitro concerted integration
catalyzed by HIV-1 IN
To assess the inhibitory effect of MAba4 on IN we used the
typical in vitro concerted integration assay using a processed LTR
as a target DNA [49]. Results reported in figures 5A and 5B
illustrate the strong inhibition effects of MAba4 on integration this
occurring with an apparent IC50 =150 ng. To learn more on the
molecular mechanism underlying the integration inhibition, we
also conducted concerted integration assays varying the preincu-
bation conditions. As shown in figure 5C, preincubation of
partners plays an important role on the outcome of the results.
Thus, when IN is preincubated with MAba4 before adding DNA,
inhibition is stronger than when IN is preincubated with DNA
before adding MAba4 (IC50,100 ng and IC50.600 ng, respec-
tively). These findings show that MAba4 exerts an important
antagonzing effect on the binding of DNA to IN, which is in
agreement with our competition ELISA results (Fig. 4).
Discussion
The use of monoclonal antibodies is proved to be of great help
in the search of functional regions in proteins and drug discovery
[58,59,60,61]. For most cases, the approach requires a linear
immunizing peptide to generate antibodies capable to cross-react
with the corresponding segment in the native protein. Literature
Figure 5. Effect of MAba4 on the HIV-1 IN activity. A: Standard concerted integration assays were performed with 1 pmole of IN in presence of
increasing amounts of MAba4. The final NaCl concentration was adjusted to 30 mM. MAba4 was added to the mixture at different concentrations and
the reaction products were loaded on a 1% agarose gel: 0 (lane 1), 10 (lane 2), 20 (lane 3), 30 (lane 4), 40 (lane 5), 50 (lane 6), 100 (lane 7), 200 lane (8),
600 (lane 9) or 800 ng (lane 10). The position and the structure of the different products obtained after half-site (HSI), full-site (FSI) and donor/donor
integration (d/d) are indicated. B: Densitometry of the FSI (full site integration) and FSI+HIS (half site integration) bands of experiments shown in A.
The different integration products were quantified using the Image J software. Panel values are the mean 6 standard deviation (error bars) of three
independent experiments. C: Inhibition assays were performed under different preincubation conditions. MAba4 was either added simultaneously to
IN and DNA ([IN+DNA+MAba4]), either after preincubation between IN and DNA ([IN+DNA]+MAba4) or it was preincubated with IN before adding the
DNA substrates ([IN+MAba4]+DNA). The different integration products detected on agarose gel were quantified using the Image J software. Panel
values are the mean 6 standard deviation (error bars) of three independent experiments.
doi:10.1371/journal.pone.0016001.g005
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recognizing the immunizing peptide and the corresponding
segment within the protein with similar efficiency [62,63,64].
However, linear peptides are generally structurally unstable
compared with segments making often difficult the interpretation
of antigen-antibody molecular recognition on a conformational
basis. For instance, K159, the linear immunizing peptide used in
the present work for preparation of the MAba4 antibody is
disordered almost on its whole length, while, in the IN CCD
crystal structures, the N-terminal portion (residues 147–166) of the
corresponding segment displays a regular helix secondary
structure, and the C-terminal portion (166–175) a flexible loop.
Despite this, MAba4 recognizes equally well the epitope within the
K159 peptide taken in isolation or as a segment within the
enzyme. The whole K159 peptide is highly antigenic. It has been
previously used to prepare polyclonal antibodies recognizing the
flexible C-terminal portion [46]. Once purified up to the stage
monospecific the antibodies cross reacted with both IN CCD and
IN, and inhibited with high efficiency the IN catalytic activity in in
vitro integration assays. Since then, several reports have shown that
the C-terminal epitope was an optimal epitope of IN (the 164/
165–172 sequence) in HIV-1 infected patients of South Africa and
Botswana [62–65]. In addition to its strong avered immunological
properties, the C-terminal portion extensively participates to the
binding of LEDGF (lens epithelium derived gross factor) [27,57], a
factor that is thought to tether the preintegration complex to
chromatin and favor integration [65,66,67]. Moreover, several
experiments have suggested its possible involvement in the nuclear
transport of IN.
The monoclonal antibody MAba4 obtained in the present work
has this time its epitope in the other extremity of K159 that is in
the N-terminal portion. Noteworthy, prediction methods have
shown that the latter was a functional epitope (‘‘Antibody Epitope
Summary’’ table, from the ‘‘HIV-1 molecular immunology
database’’ of Los Alamos; (http://www.hiv.lanl.gov/content/
immunology), revealing that experimental results and predictions
can be in perfect agreement. However, the C-terminal and the N-
terminal portions have completely different conformational
properties. While the C-terminal portion is mainly disordered
whatever is the context, the N-terminal portion accommodates
either an amphipathic helix structure (i.e. in the CCD crystal,
thanks to the tertiary structure interactions) or a mainly disordered
structure (i.e. in K159, in response to water exposure of amino
acid residues). The main question is how MAba4 can bind with an
apparent similar efficiency an epitope under both the random coil
structure and the helix conformation?
Actually, the N-terminal portion of K159 presents intrinsic a-
helix forming properties, as it easily recovers a stable helical
conformation in trifluoroethanol, an organic solvent known for its
helix enhancer properties [55]. Therefore the N-terminal portion
could assume an equilibrium of different conformations with either
a low energy barrier between the helix and the other conforma-
tions or an entropic effect that only weakly contributes to the a-
helix selection. These could explain why in ELISA essays the
antibody binds with equal efficiency the epitope either as a stable
helix, within IN and K156, or an instable helix, within K159 and
pep-a4. This ability of the antibody to select a stable conformation
is conform to recent molecular modeling calculations which
indicate that a proportion of short antigenic peptides could adopt
the desired stable conformations and generate antibodies that in
turn will recognize this conformation within the native proteins
[64]. It could be also that: the antigenic peptide presents the ability
of eliciting a number of conformationally different antibodies each
of them recognizing a particular antigenic conformation; or, a
single antibody binding site adopts several conformations, each of
them capturing a complementary antigen conformation, among a
family of preexisting antigen conformations.
Anyway, it appears that the antibody and the DNA have
completely different requirements for the binding to IN. The
recognition of the epitope by the antibody seems less selective than
that of the corresponding peptide by its cognate DNA. In the latter
case a pre-stabilization of the peptide in a-helix is required to
obtain a specific binding [26].
Finally, the inhibitory properties of the antibody seem them also
interesting. Both competition ELISA assays and concerted
integration assays under preincubation conditions show that the
inhibition mechanism proceeds by means of an impediment of the
binding of IN to its cognate DNA. Obviously, these findings
reinforce the idea of a significant contribution of the IN a4- helix
in the recognition of the viral DNA LTRs.
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